2021-08-12T19:59:56-05:00 2020-09-30 ERNST & YOUNG US LLP 101 E WASHINGTON ST STE 910 PHOENIX AZ 85004 990 2019-10-01 753065445 THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE % KEVIN GROFF TRAN 6023438400 445 N 5TH STREET Suite 600 PHOENIX AZ 85004 MANUEL ESTRADA CFO 6023438400 2021-08-09 true PATRICK SHIELDS P01508556 6023223000 2021-08-12 2019 2022-09-23 18:48:47Z JEFFREY M TRENT PHD 445 N 5TH STREET PHOENIX AZ 85004 83920797 false X WWW.TGEN.ORG X 2002 AZ SEE SCHEDULE O 13 10 419 62 0 0 62343578 54124639 17942426 23939255 479922 406035 -3337378 -4320536 77428548 74149393 0 0 0 0 30375329 37899661 0 0 0 34497493 40903399 64872822 78803060 12555726 -4653667 140891715 140363431 58482929 62473382 82408786 77890049 X SEE SCHEDULE O false false 18388607 0 10645477 CLINICAL GENOMICS REFERENCE LABORATORY - SEE SCHEDULE O 8406478 0 7460949 PATHOGEN AND MICROBIOME - SEE SCHEDULE O 5000535 0 3202871 INTEGRATED CANCER - SEE SCHEDULE O 26486613 0 2653958 58282233 true true false true false false false false true true true false false true true true true true false false true false false false false false false false false true false false false true false false false true false false false false true true true true false false true 76 0 true 419 true false false false false false false false false false false false false X 13 10 false false false false true true true true true false false true true true true true true true true false X KEVIN GROFF 6023438478 445 N 5TH STREET SUITE 600 PHOENIX AZ 85004 ROBERT STONE BD & VICE CHRM/COH CEO & PRES. 1.0 59.0 X X 0 3717559 507612 JENNIFER PARKHURST TREASURER/COH CFO 1.0 59.0 X 0 1131123 350199 JEFFREY M TRENT PHD BOARD MEMBER/PRES/SCIENCE DIR. 39.0 1.0 X X 0 1332028 52921 GREGORY SCHETINA SECRETARY/COH GENERAL COUNSEL 1.0 59.0 X 0 1060596 195382 DANIEL VON HOFF PHYSICIAN IN CHIEF 40.0 0.0 X 875090 0 21764 CORNELIS VAN DEN BERG FORMER TREASURER 0.0 60.0 X 0 697350 54209 TERESA BURLESON CHIEF OPERATING OFFICER 39.0 1.0 X 534670 0 117669 SUNIL SHARMA DEPUTY DIR OF CLINIC. SCIENCES 40.0 0.0 X 549285 0 21450 MICHAEL BERENS DEPUTY DIRECTOR OF RESEARCH 40.0 0.0 X 488370 0 30518 NICHOLAS SCHORK PROFESSOR 40.0 0.0 X 383895 0 19559 JULIA BRIDGE PROFESSOR 40.0 0.0 X 388575 0 13155 THOMAS ROYCE ASHION EXECUTIVE DIRECTOR 40.0 0.0 X 373827 0 21510 STEPHANIE MCRAE GENERAL COUNSEL/ASST SECRETARY 40.0 0.0 X 328707 0 16464 MANUEL ESTRADA CFO/ASSISTANT TREASURER 39.0 1.0 X 319895 0 20250 TIMOTHY MCDANIEL SR. VP OF EMERG. OPPORTUNITIES 40.0 0.0 X 308000 0 23258 JAMES LOWEY CHIEF INFORMATION OFFICER 40.0 0.0 X 272259 0 15340 JANINE LOBELLO ASHION CLINICAL LAB DIRECTOR 40.0 0.0 X 264789 0 14783 KENDALL JENSEN DEPUTY DIR. OF RESEARCH RES. 40.0 0.0 X 252861 0 20326 JOHANNA DISTEFANO PROFESSOR 40.0 0.0 X 253879 0 13537 WILLIAM J POST BOARD MEMBER/CHAIRMAN 1.0 1.0 X X 0 0 0 ROBERT BULLA BOARD MEMBER 1.0 0.0 X 0 0 0 BENNETT DORRANCE BOARD MEMBER 1.0 1.0 X 0 0 0 DAVID J GULLEN MD BOARD MEMBER 1.0 0.0 X 0 0 0 SHARON HARPER BOARD MEMBER 1.0 0.0 X 0 0 0 PAMELA KEHALY BOARD MEMBER 1.0 0.0 X 0 0 0 CINDY PARSEGHIAN BOARD MEMBER 1.0 0.0 X 0 0 0 TERRY PEETS BOARD MEMBER 1.0 0.0 X 0 0 0 MARILYN QUAYLE BOARD MEMBER 1.0 0.0 X 0 0 0 ANTHONY SCOTT Board Member 1.0 0.0 X 0 0 0 RICHARD SILVERMAN BOARD MEMBER 1.0 0.0 X 0 0 0 5594102 7938656 1529906 64 true true false Girikon LLC 15433 N TATUM BLVD SUITE 105 PHOENIX AZ 85032 CONSULTING SERVICES 249876 BOOTH UDALL FULLER PLC 1255 W RIO SALADO PKWY SUITE 215 TEMPE AZ 85281 LEGAL SERVICES 225938 FIRSTSTRATEGIC 300 W CLARENDON AVE SUITE 460 PHOENIX AZ 85013 CONSULTING SERVICES 216000 TECH66 LLC 4557 E VIA LOS CABALLOS PHOENIX AZ 85028 CONSULTING SERVICES 157842 ASG GROUP LLC 30 POVERTY ROAD SOUTHBURY CT 06488 CONSULTING SERVICES 111000 5 36052687 8467201 9604751 19445 54124639 RESEARCH CONTRACTS 541711 23939255 23939255 0 0 23939255 139512 139512 0 0 2917029 7261565 -4344536 0 -4344536 -4344536 858926 1917436 709084 1800755 149842 116681 266523 266523 0 0 0 0 0 0 0 0 0 ALL OTHER REVENUE 900099 24000 24000 0 0 24000 74149393 23963255 0 -3938501 X 0 0 0 0 0 0 0 0 4843763 2187063 2656700 0 0 0 0 0 27956010 18185934 9770076 0 964020 597856 366164 0 2180595 1343468 837127 0 1955273 938605 1016668 0 0 0 0 0 486324 3026 483298 0 294766 10010 284756 0 129600 0 129600 0 0 0 0 0 0 0 9390122 7616665 1773457 0 266575 26971 239604 0 16056989 15249502 807487 0 2486905 1748198 738707 0 0 0 0 0 443357 333387 109970 0 398424 206403 192021 0 0 0 0 0 248262 143058 105204 0 142476 38861 103615 0 0 0 0 0 7620918 7270173 350745 0 361916 65326 296590 0 BAD DEBT EXPENSE 2170915 2161210 9705 0 RECRUITMENT 202069 111053 91016 0 DUES & SUBSCRIPTION 149032 45377 103655 0 RELOCATION 31227 87 31140 0 23522 23522 78803060 58282233 20520827 0 0 14053892 21756000 6122458 6429969 11990764 12511721 1135090 2479127 175000 131482 0 0 0 0 1206243 1221231 1311887 1020134 82013230 19308788 63351563 62704442 0 0 0 0 1627867 0 9118329 9093349 30798622 23015976 140891715 140363431 9342928 11933405 0 0 3286229 3103374 0 0 426199 213099 50000 50000 43944912 45982796 50000 50000 1382661 1140708 58482929 62473382 X 72631994 68899823 9776792 8990226 82408786 77890049 140891715 140363431 -4653667 176849 0 -41919 0 X false true X true true true X 67494504 17588654 31879587 62343578 54124639 233430962 0 0 67494504 17588654 31879587 62343578 54124639 233430962 7482414 225948548 143205 109024 4179409 3155820 3056541 10643999 0 5677144 5677144 249752105 100800884 0.90469 0.88910 X SCHEDULE A, PART II THE AMOUNTS INCLUDED IN SCHEDULE A, PART II CORRESPOND TO THE FOLLOWING PERIODS: COLUMN (E) 2019 : 10/01/2019-09/30/2020 COLUMN (D) 2018 : 10/01/2018-09/30/2019 COLUMN (C) 2017 : 10/01/2017-09/30/2018 COLUMN (B) 2016 : 01/01/2017-09/30/2017 (SHORT PERIOD) COLUMN (A) 2015 : 01/01/2016-12/31/2016 RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED false false false 0 false 0 false 0 false 0 false 0 false 0 true 129600 129600 false SCHEDULE C, PART II-B, LINE 1I THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (TGEN) USES A THIRD PARTY COMMUNICATIONS AND PUBLIC AFFAIRS FIRM TO COORDINATE LOBBYING EFFORTS ON BEHALF OF TGEN THROUGH COMMUNICATIONS TO LOCAL GOVERNMENT, LEGISLATIVE AND FEDERAL OFFICIALS AND COMMUNITY LEADERS ON TGEN ACTIVITIES. false true X 6186285 378481 419824 287763 6696827 5088052 1373720 227248 502735 6186285 5355690 75833 182488 525959 5088052 5258044 46076 525676 4658 469448 5355690 5384983 374012 500951 5258044 0.00000 0.28410 0.71590 false true true 0 47449788 3063432 44386356 3256831 1610221 1646610 25584495 12870676 12713819 5722116 1764459 3957657 62704442 DUE FROM CITY OF HOPE 11500707 DUE FROM TGEN FOUNDATION 10374561 INVESTMENT IN 457(B) PLAN 1140708 23015976 0 DUE TO EMPLOYEE 457(B) PLAN 1140708 1140708 X 74149393 0 0 74149393 0 0 74149393 78803060 0 0 78803060 0 0 78803060 SCHEDULE D, PART IV, LINE 2B CERTAIN TENANT RENTAL OVER PAYMENTS WERE TRANSFERRED IN THE OCTOBER 2017 BUILDING TRANSACTION WITH THE CITY OF PHOENIX. PER THE TENANT LEASES, AMOUNTS WILL BE PAID IN CASH AND CREDITS OVER A FOUR YEAR PERIOD ENDING IN SEPTEMBER 2021. SCHEDULE D, PART V, LINE 4 TGEN'S POLICY FOR APPROPRIATING THE DISTRIBUTION OF ITS SUMMER INTERNSHIP PROGRAM ENDOWMENT HAS BEEN DESIGNED TO SUPPORT A SPECIFIC NUMBER OF SUMMER INTERNS EACH YEAR FOR 25 YEARS. THE INSTITUTE CONSIDERED THE LONG-TERM EXPECTED RETURN ON ITS ENDOWMENT. TGEN FOUNDATION CLASSIFIES AS PERMANENTLY RESTRICTED NET ASSETS (1) THE ORIGINAL VALUE OF THE GIFT DONATED TO THE PERMANENT ENDOWMENT, (2) THE ORIGINAL VALUE OF SUBSEQUENT GIFTS DONATED TO THE PERMANENT ENDOWMENT, AND (3) ACCUMULATIONS TO THE PERMANENT ENDOWMENT MADE IN ACCORDANCE WITH THE DIRECTION OF THE APPLICABLE DONOR GIFT INSTRUMENT. TGEN FOUNDATION HAS A TEMPORARILY RESTRICTED ASSET WHICH HAS BEEN DESIGNED TO SUPPORT A SUMMER INTERN EACH YEAR AT TGEN. TGEN FOUNDATION'S POLICY FOR APPROPRIATING THE DISTRIBUTION OF ITS SUMMER INTERNSHIP PROGRAM ENDOWMENT HAS BEEN DESIGNED TO SUPPORT A GRANT TO TGEN FOR AN INTERN EACH YEAR FOR 20 YEARS. THE FOUNDATION CONSIDERED THE LONG-TERM EXPECTED RETURN ON ITS ENDOWMENT. TGEN FOUNDATION HAS A RESTRICTED ASSET FOR THE ESTABLISHMENT OF AN ENDOWED CHAIR IN BRAIN CANCER RESEARCH. TGEN FOUNDATION ALSO HAS A RESTRICTED ASSET WHICH ALLOWS THEM TO USE ANY INVESTMENT INCOME FOR OPERATING EXPENSES. SCHEDULE D, PART XIII TGEN AND THE FOUNDATION ARE EXEMPT FROM INCOME TAXES UNDER SECTION 501(C)(3) OF THE U.S. INTERNAL REVENUE CODE. TGEN AND THE FOUNDATION ARE EXEMPT FROM ARIZONA CORPORATE INCOME TAX UNDER SECTION 43-1201(A) OF THE ARIZONA REVISED STATUTES (A.R.S.) ACCORDINGLY, NO PROVISION FOR INCOME TAX IS INCLUDED IN THE ACCOMPANYING CONSOLIDATED FINANCIAL STATEMENTS. TGEN AND THE FOUNDATION HAVE NO SIGNIFICANT UNCERTAIN TAX POSITIONS OR TAX LIABILITY FOR TAX BENEFITS, INTEREST, OR PENALTIES ACCRUED AT SEPTEMBER 30, 2020. Europe (Including Iceland and Greenland) Program services RESEARCH SERVICES 149224 North America Program services RESEARCH SERVICES 28362 South Asia Program services RESEARCH SERVICES 9600 Middle East and North Africa Program services RESEARCH SERVICES 2431 East Asia and the Pacific Program services RESEARCH SERVICES 395 190012 190012 false false false false false false SCHEDULE F, PART I, LINE 3, COLUMN (F) THE AMOUNTS REPORTED IN COLUMN (F) ARE DETERMINED BASED ON THE ACCRUAL METHOD OF ACCOUNTING. X X X X false true false false false false false true false JEFFREY M TRENT PHD BOARD MEMBER/PRES/SCIENCE DIR. 0 815491 0 427500 0 89037 0 22684 0 30237 0 1384949 0 0 ROBERT STONE BD & VICE CHRM/COH CEO & PRES. 0 1471214 0 2116992 0 129353 0 468184 0 39428 0 4225171 0 397500 TERESA BURLESON CHIEF OPERATING OFFICER 482828 0 50000 0 1842 0 107327 0 10342 0 652339 0 0 0 MANUEL ESTRADA CFO/ASSISTANT TREASURER 275385 0 43100 0 1410 0 8409 0 11841 0 340145 0 0 0 JAMES LOWEY CHIEF INFORMATION OFFICER 234669 0 35809 0 1781 0 10971 0 4369 0 287599 0 0 0 STEPHANIE MCRAE GENERAL COUNSEL/ASST SECRETARY 270131 0 56734 0 1842 0 2606 0 13858 0 345171 0 0 0 JENNIFER PARKHURST TREASURER/COH CFO 0 727272 0 396984 0 6867 0 304055 0 46144 0 1481322 0 0 GREGORY SCHETINA SECRETARY/COH GENERAL COUNSEL 0 524386 0 490550 0 45660 0 145280 0 50102 0 1255978 0 118210 MICHAEL BERENS DEPUTY DIRECTOR OF RESEARCH 344579 0 120000 0 23791 0 18521 0 11997 0 518888 0 97222 0 TIMOTHY MCDANIEL SR. VP OF EMERG. OPPORTUNITIES 265165 0 41593 0 1242 0 10210 0 13048 0 331258 0 0 0 SUNIL SHARMA DEPUTY DIR OF CLINIC. SCIENCES 498443 0 30000 0 20842 0 8616 0 12834 0 570735 0 0 0 DANIEL VON HOFF PHYSICIAN IN CHIEF 720164 0 150000 0 4926 0 9736 0 12028 0 896854 0 108333 0 THOMAS ROYCE ASHION EXECUTIVE DIRECTOR 283287 0 90000 0 540 0 11180 0 10330 0 395337 0 0 0 JANINE LOBELLO ASHION CLINICAL LAB DIRECTOR 264249 0 0 0 540 0 10711 0 4072 0 279572 0 0 0 JOHANNA DISTEFANO PROFESSOR 241856 0 10203 0 1820 0 9147 0 4390 0 267416 0 0 0 KENDALL JENSEN DEPUTY DIR. OF RESEARCH RES. 242021 0 9626 0 1214 0 6027 0 14299 0 273187 0 0 0 JULIA BRIDGE PROFESSOR 365559 0 20000 0 3016 0 4159 0 8996 0 401730 0 0 0 NICHOLAS SCHORK PROFESSOR 359603 0 21970 0 2322 0 11132 0 8427 0 403454 0 0 0 CORNELIS VAN DEN BERG FORMER TREASURER 0 466406 0 186511 0 44433 0 28213 0 25996 0 751559 0 0 SCHEDULE J, PART I, LINE 4B CERTAIN CITY OF HOPE'S EXECUTIVES PARTICIPATE IN THE CITY OF HOPE'S NON-QUALIFIED 457(F) EXECUTIVE SUPPLEMENTAL ACCUMULATION PLAN THAT IS DESIGNED AND MAINTAINED TO PROVIDE A SELECT GROUP OF MANAGEMENT OR HIGHLY COMPENSATED EMPLOYEES WITH DEFERRED COMPENSATION. THE PLAN VESTS AFTER THREE (3) FISCAL YEARS OF SERVICES AND THE VESTED TOTALS ARE INCLUDED IN SCHEDULE J, PART II, COLUMN B (III). PRIOR TO VESTING, THE ANNUAL AMOUNTS ARE INCLUDED IN SCHEDULE J, PART II, COLUMN C. PURSUANT TO THE PLAN DOCUMENTS, VESTED PARTICIPANTS ARE ENTITLED TO WITHDRAW FROM THEIR VESTED ACCOUNT AN AMOUNT EQUAL TO THE FEDERAL, STATE, LOCAL, AND FICA TAXES THEY OWE. THESE AMOUNTS ARE REMITTED TO THE APPROPRIATE TAXING AUTHORITIES ON BEHALF OF THE PARTICIPANTS. DURING THE CALENDAR YEAR ENDING DECEMBER 31, 2019, THE FOLLOWING INDIVIDUALS WITHDREW THE REFERENCED AMOUNTS TO COVER SUCH TAXES: ROBERT STONE $34,762 GREGORY SCHETINA $9,352 THESE AMOUNTS HAVE BEEN INCLUDED IN THE PARTICIPANTS INCOME ON SCHEDULE J, PART II, COLUMN B (III). SCHEDULE J, PART I, LINE 7 SOME OF TGEN'S OFFICERS AND KEY EMPLOYEES LISTED IN PART VII WERE PAID BONUSES WHICH WERE BASED ON ACCOMPLISHMENTS OF SPECIFIC MILESTONES AND/OR PERFORMANCE METRICS, AS APPROVED BY THE TGEN BOARD OF DIRECTORS. SCHEDULE J, PART II SOME OF TGEN'S OFFICERS AND KEY EMPLOYEES LISTED IN PART VII HAVE RETENTION AGREEMENTS THROUGH 2019, 2020 AND 2021. AMOUNTS ACCRUED BY TGEN DURING CALENDAR YEAR 2019 UNDER THESE AGREEMENTS HAVE BEEN REPORTED IN SCHEDULE J, PART II, COLUMN (C) AS DEFERRED COMPENSATION. BENNETT DORRANCE BOARD MEMBER SEE PART V X 50000 50000 false true true KENDALL JENSEN EMPLOYEE RELOCATION ASSIST. X 250000 125000 false true true 175000 TECH66 LLC WILLIAM BURLESON SPOUSE OF OFFICER 200852 CONSULTING FEES false SCHEDULE L, PART II, LINE 1, COLUMN (C) CAPITALIZE NEW ENTITY FORMED FOR BIOMARKER RESEARCH. FORM 990, PART I, LINE 1 and PART III, LINE 1 THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (TGEN) IS A NONPROFIT BIOMEDICAL RESEARCH INSTITUTE FOCUSED ON DEVELOPING EARLIER AND SMARTER TREATMENTS BY EMPLOYING INNOVATIVE ADVANCES ARISING FROM THE HUMAN GENOME PROJECT AND APPLYING THEM TO THE DEVELOPMENT OF DIAGNOSTICS, PROGNOSTICS AND THERAPIES FOR CANCER, NEUROLOGICAL DISORDERS, DIABETES AND OTHER COMPLEX DISEASES. FORM 990, PART III, LINE 4A TGEN'S CLINICAL GENOMIC SEQUENCING IS PROVIDED THROUGH ASHION, A TGEN SPECIALTY LAB, ESTABLISHED IN 2011, WHICH IS A CAP ACCREDITED AND CLIA-CERTIFIED TESTING LABORATORY COMMITTED TO ACCELERATING THE ADOPTION OF PRECISION MEDICINE IN THE CARE STREAM. THE LABORATORY USES NEXT-GENERATION SEQUENCING TECHNOLOGY AND PROPRIETARY INFORMATICS SYSTEMS FOR ANALYSIS AND DRUG MATCHING. TUMOR/NORMAL SEQUENCING IS PERFORMED FOR ALL OF TGEN'S PRECISION MEDICINE ONCOLOGY TRIALS. THE LABORATORY ALSO PROVIDES GENOMIC SEQUENCING SERVICES FOR TGEN'S CENTER FOR RARE CHILDHOOD DISORDERS. THE TEST MENU INCLUDES CLIA-CERTIFIED EXOME AND RNA SEQUENCING. FORM 990, PART III, LINE 4B THE PATHOGEN AND MICROBIOME DIVISION IS FOCUSED ON DEVELOPING AND TRANSLATING MICROBIAL GENOMIC DISCOVERIES INTO APPLICATION TO ADVANCE HUMAN HEALTH IN THE AREAS OF CLINICAL MEDICINE, PUBLIC HEALTH AND BIODEFENSE. THE DIVISION SEEKS TO ADVANCE OUR UNDERSTANDING OF MULTI-DRUG RESISTANT INFECTIONS, DEVELOP NOVEL GENOTYPING TECHNIQUES FOR GENOMIC EPIDEMIOLOGY AND MICROBIAL FORENSICS, FUNGAL EPIDEMIOLOGY AND PHYLOGENETICS, UNDERSTAND THE RELATIONSHIP OF MICROBES TO HUMAN HEALTH AND DISEASE, AND THROUGH THE TGEN NORTH CLIA LAB OFFER PCR AND SEROLOGY TESTING FOR SARS-COV-2. A MAJOR EMPHASIS IS ON ADAPTING AND ADVANCING NEXT-GENERATION SEQUENCING TOOLS FOR INFECTIOUS DISEASE RESEARCH AND HEALTHCARE SUCH AS DIAGNOSTIC TESTS TO CHARACTERIZE AND TRACK HOSPITAL ACQUIRED INFECTIONS, WITH AN EMPHASIS ON ANTIBIOTIC RESISTANCE, ALLOWING PHYSICIANS TO PROVIDE PERSONALIZED THERAPY AND CONTAIN OUTBREAKS. ASSAYS HAVE BEEN TAILORED TO MANY DISEASES, ORGANISMS AND SAMPLE TYPES, INCLUDING MRSA, TUBERCULOSIS, KLEB, E COLI AND STAPHYLOCOCCUS. THE DIVISION WORKS CLOSELY WITH ITS SISTER INSTITUTE AT NORTHERN ARIZONA UNIVERSITY, THE PATHOGEN AND MICROBIOME INSTITUTE, AS WELL AS WITH A NUMBER OF OTHER COLLABORATORS LOCALLY, NATIONALLY AND GLOBALLY. THE DIVISION HAS BEEN INSTRUMENTAL IN SOLVING NUMEROUS DISEASE OUTBREAKS AROUND THE WORLD, HAS GENERATED MULTIPLE INVENTIONS AND HAS LICENSED OUT INTELLECTUAL PROPERTY TO GOVERNMENTS AND BIOTECH COMPANIES. FORM 990, PART III, LINE 4C THE DIVISION OF INTEGRATED CANCER GENOMICS IS UTILIZING STATE-OF-THE-ART MOLECULAR TECHNOLOGIES TO UNCOVER THE MULTIPLE DIMENSIONS OF MOLECULAR CHANGES THAT OCCUR IN CANCER, AND INTEGRATE THESE DATASETS TO CAPTURE A HIGH-RESOLUTION IMAGE OF THE TUMOR MOLECULAR LANDSCAPE. AMONG ICG FACULTY, THE DIVISION BOASTS AN AMAZING ARRAY OF COMPETENCIES INCLUDING GENOMIC PROFILING USING VARIOUS TECHNOLOGIES THAT INCLUDE NEXT-GENERATION SEQUENCING INCLUDING SINGLE-CELL, EPIGENETICS, NEOANTIGEN ANALYSIS, CANCER CELL BIOLOGY AND BIOINFORMATICS. ACROSS THE VARIOUS LABORATORIES, WE STUDY A MULTITUDE OF ADULT AND PEDIATRIC CANCERS, TRYING TO UNDERSTAND THE EVENTS THAT DRIVE CANCER PROGRESSION FROM PRIMARY TO ADVANCED METASTATIC DISEASE IN ADDITION TO UNDERSTANDING WHY AND HOW CANCER AFFECTS INDIVIDUALS FROM DIFFERENT ETHNICITIES AND ANCESTRAL BACKGROUNDS. ICG FACULTY ALSO ARE INVOLVED IN APPLYING HIGH-RESOLUTION GENOMIC TECHNOLOGIES TO PATIENT SAMPLES IN REAL TIME, DURING CLINICAL MANAGEMENT, TO ASSIST ONCOLOGISTS IN MAKING THERAPEUTIC RECOMMENDATIONS FOR CANCER PATIENTS. ICG IS DIRECTLY AIMING ITS EFFORTS TO DRIVE EARLIER DIAGNOSTICS AND SMARTER TREATMENTS TOWARDS PATIENTS. FORM 990, PART III, LINE 4D RESEARCH PROGRESSED MARKEDLY IN 2020, RESULTING IN SIGNIFICANT RESULTS ACROSS A NUMBER OF BIOMEDICAL INVESTIGATIONS; FROM ALZHEIMER'S DISEASE TO CHILDREN'S BRAIN CANCER, COMPARATIVE ONCOLOGY AND DIABETES. VALIDATION OF TECHNOLOGY SUPPORTING THE MANY POTENTIAL FACETS OF TGEN'S CENTER FOR NONINVASIVE DIAGNOSTICS CREATED NEW OPPORTUNITIES AND NEW PATHWAYS FOR DIAGNOSING DISEASE. TGEN'S CAPABILITIES AND STRENGTH IN GENOMICS ALSO CAME TO THE FORE WHEN THE THREAT POSED BY SARS-COV-2 BECAME AN INTERNATIONAL PUBLIC THREAT. WITHIN DAYS OF HEARING OF THE POTENTIALLY DEADLY SARS-COV-2, TGEN NORTH SCIENTISTS BEGAN DEVELOPING A GENOMIC-BASED CLINICAL TEST TO CONFIRM INFECTION. FIVE WEEKS LATER, THE SCIENTISTS AT TGEN NORTH RECEIVED FDA EMERGENCY-USE AUTHORIZATION FOR A PCR-BASED GENETIC TEST FOR THE SARS-COV-2, WHILE SIMULTANEOUSLY STANDING UP AND RECEIVING STATE CERTIFICATION FOR ITS CLIA LABORATORY, A STEP NECESSARY TO RETURN TESTING RESULTS TO PATIENTS AND THEIR PHYSICIANS. THIS IS A TESTAMENT TO THE FORESIGHT OF TGEN NORTH LEADERSHIP WHO IN 2018 PUT TOGETHER TGEN'S ONE HEALTH COLLABORATIVE, AN INITIATIVE FOR PROTECTING PUBLIC HEALTH AND THE ENVIRONMENT, WORKING WITH LOCAL, STATE, FEDERAL AND INTERNATIONAL PUBLIC HEALTH OFFICIALS AND OTHERS TO TRACK THE CAUSE AND SOURCE OF DISEASE OUTBREAKS, ANTIBIOTIC RESISTANCE, HOSPITAL-ACQUIRED INFECTIONS, MICROBIAL EVOLUTION, PATHOGEN DISPERSAL, AND EMERGING INFECTIONS. WHILE SARS-COV-2 MAY HAVE SHAPED HOW WE WORKED AND LIVED FOR MUCH OF THE YEAR, IT DID NOT IMPEDE THE PROGRESS OF OUR FACULTY, NOR OUR COLLEAGUES AT CITY OF HOPE AND BEYOND. WHILE OUR WORK TOWARD SAFEGUARDING OUR COMMUNITIES AGAINST SARS-COV-2 BECAME PARAMOUNT, EFFORTS AROUND OUR CORE MISSION - HELPING PATIENTS SUFFERING FROM CANCER, NEUROLOGICAL DISEASES, DIABETES AND RARE CHILDHOOD DISORDERS - NEVER WANED. TGEN'S PARTNERSHIPS HAVE RESULTED IN VARIOUS MULTI-YEAR, MULTI-MILLION DOLLAR EFFORTS FUNDED BY THE NATIONAL INSTITUTES OF HEALTH CENTERED ON: CHLOROTOXIN-PREDICTED CHIMERIC ANTIGEN RECEPTOR T CELLS FOR TREATMENT IN GLIOBLASTOMA, A SCALABLE PLATFORM FOR HIGHLY-MULTIPLEXED ANALYSIS OF ANTIBODY REACTIVITY FROM 1UL OF BLOOD, AND TREATMENT MONITORING IN EARLY AND LOCALLY ADVANCED BREAST CANCER USING CIRCULATING TUMOR DNA ANALYSIS. ADDITIONALLY, TGEN INVESTIGATORS WERE AWARDED GRANTS IN MULTIPLE FIELDS, INCLUDING NEUROGENOMICS, CANCER THERAPEUTICS AND TREATMENTS, AND DISEASE DETECTION AND MONITORING. TGEN ADVANCED A SERIES OF INNOVATIVE RESEARCH INITIATIVES THAT YIELDED NUMEROUS SCIENTIFIC DISCOVERIES (MANY WITH POTENTIAL CLINICAL APPLICATION), ESTABLISHED NATIONAL AND INTERNATIONAL COLLABORATIONS, AND LED NEW AND EXCITING CLINICAL TRIALS WITH PROMISING RESULTS IN THE AREAS OF PATHOGENIC DISEASE, CANCER DIAGNOSIS AND MONITORING, NEUROGENOMICS, AND CANINE CANCER. SPECIFICALLY, TGEN INVESTIGATORS ARE SEQUENCING SAMPLES FROM SARS-COV-2 PATIENTS TO ANALYZE THE VIRUS' GENETIC CODES AND TRACK ITS DIFFERENT STRAINS, IDENTIFYING THAT CERTAIN GENETIC ALTERATIONS IN KIDNEY CANCER TUMORS PREDICT WHICH PATIENTS WILL FAIL TO RESPOND TO THE LATEST CANCER DRUGS WHICH WORK BY BOOSTING THE PATIENT'S IMMUNE SYSTEM, DETECTING A PREDATOR-PREY RELATIONSHIP BETWEEN CIRCULATING IMMUNE CELL DYNAMICS AND TUMOR RESPONSE TO IMMUNOTHERAPY, USING ORGANOIDS, ORGAN-LIKE LABORATORY CULTURES DERIVED FROM PATIENT TUMORS, TO PROVIDE A NEW LEVEL OF ACCURACY IN PRESCRIBING ANTI-CANCER TREATMENTS, AND DETECTING UNIQUE LUNG CELLS THROUGH ONE OF THE FIRST COMPREHENSIVE LOOKS AT THE CELLS USING A TECHNOLOGY CALLED SINGLE-CELL RNA SEQUENCING THAT MAY DRIVE IDIOPATHIC PULMONARY FIBROSIS, A DEADLY LUNG DISEASE THAT AFFECTS HUNDREDS OF THOUSANDS OF AMERICANS AND FOR WHICH THERE IS NO CURE. TGEN INVESTIGATORS PUBLISHED THEIR RESEARCH RESULTS EXTENSIVELY IN SCHOLARLY PEER-REVIEWED ACADEMIC JOURNALS AND PRESENTED VIRTUALLY AT LEADING NATIONAL AND INTERNATIONAL CONFERENCES; INCLUDING PUBLICATION IN LEADING SCIENTIFIC JOURNALS SUCH AS AMERICAN JOURNAL OF HUMAN GENETICS, CELL, NATURE COMMUNICATIONS, JOURNAL OF NEUROSCIENCE, CLINICAL CANCER RESEARCH, JAMA NEUROLOGY, NEUROLOGY, NEW ENGLAND JOURNAL OF MEDICINE, SCIENCE TRANSLATIONAL MEDICINE, AND PRESENTATIONS AT LEADING CONFERENCES SUCH AS THE SU2C SCIENTIFIC SUMMIT. TGEN INVESTIGATORS FURTHER SERVE AS RESOURCES TO MEDICAL AND SCIENTIFIC RESEARCH CENTERS THROUGHOUT THE COUNTRY IN THEIR AREAS OF RESEARCH. IN EDUCATION AND OUTREACH, TGEN PROVIDED VIRTUAL INTERNSHIPS TO STUDENTS IN PROGRAMS THAT FOCUSED ON DEVELOPING PROFESSIONAL AND SCIENTIFIC SKILLS. ADDITIONALLY, TGEN PROVIDED A VIRTUAL BIOSCIENCE LEADERSHIP ACADEMY FOR STUDENTS WHERE THEY LEARNED ABOUT A VARIETY OF TOPICS WITHIN THE THEMES OF PROFESSIONAL DEVELOPMENT, LEADERSHIP, TRANSLATIONAL MEDICINE, AND HOT TOPICS IN THE BIOSCIENCES. FORM 990, PART VI, LINE 6 THE SOLE CORPORATE MEMBER OF TGEN IS CITY OF HOPE. FORM 990, PART VI, LINE 7A THE AFFILIATION AGREEMENT BETWEEN TGEN AND CITY OF HOPE GRANTS CITY OF HOPE THE RIGHT TO APPOINT DIRECTORS. FORM 990, PART VI, LINE 7B CERTAIN ACTIONS MAY NOT BE UNDERTAKEN WITHOUT THE PRIOR WRITTEN APPROVAL OF THE SOLE CORPORATE MEMBER, CITY OF HOPE, AS SPECIFIED IN THE GOVERNING DOCUMENTS OF TGEN, ON BEHALF OF ITSELF OR CERTAIN AFFILIATES, INCLUDING: BORROW OR LEND MONEY OR PLEDGE PROPERTY AS SECURITY; FIX COMPENSATION FOR DIRECTORS; CHANGE THE NUMBER OF VOTING DIRECTORS; ASSIGN, TRANSFER, PLEDGE, COMPROMISE OR RELEASE CERTAIN CLAIMS OR DEBTS; COMMENCE ASSIGNMENT FOR THE BENEFIT OF CREDITORS, PETITION FOR REORGANIZATION OR SIMILAR RELIEF OR ACTION; ACQUIRE, PURCHASE, DEVELOP, MATERIALLY IMPROVE, SELL, LEASE, OR MORTGAGE CORPORATE REAL ESTATE; MERGE, DISSOLVE OR SELL ALL OR SUBSTANTIALLY ALL ASSETS; ADOPT BUDGETS, STRATEGIC PLANS OR MATERIAL CHANGES TO OPERATIONS; FORM AFFILIATES OR MAKE BUSINESS INVESTMENTS; ADOPT, REPEAL OR AMEND KEY GOVERNING DOCUMENTS; EXERCISE CERTAIN GOVERNANCE RIGHTS; INCUR LIABILITIES OR CONTRACT OTHER THAN FOR FAIR CONSIDERATION AND IN THE ORDINARY COURSE OF BUSINESS. FORM 990, PART VI, LINE 11B THE FORM 990 IS PREPARED BY AN OUTSIDE ACCOUNTING FIRM BASED ON INFORMATION PROVIDED BY THE TGEN FINANCE DEPARTMENT. THE FORM 990 IS THEN REVIEWED BY THE FINANCE DEPARTMENT, OTHER MEMBERS OF MANAGEMENT AND THE AUDIT AND COMPLIANCE COMMITTEE OF THE CITY OF HOPE. THE FORM 990 IS POSTED ON THE BOARD WEBSITE FOR BOARD REVIEW PRIOR TO FILING WITH THE IRS. FORM 990, PART VI, LINE 12C TGEN DISTRIBUTES A CONFLICT OF INTEREST QUESTIONNAIRE ANNUALLY TO ALL DIRECTOR LEVEL POSITIONS AND ABOVE, IN ADDITION TO ANY OFFICERS AND KEY EMPLOYEES DESIGNATED BY THE CONFLICT OF INTEREST COMMITTEE. THE QUESTIONNAIRES ARE REVIEWED BY TGEN'S FINANCE DEPARTMENT AND THE OFFICE OF RESEARCH COMPLIANCE. THOSE EMPLOYEES WITH CONFLICTS ARE SENT FOR FURTHER REVIEW TO THE CONFLICT OF INTEREST COMMITTEE TO ENSURE AN APPROPRIATE PLAN IS SET FORTH. UPDATES TO THE LIST ARE HANDLED ON AN AS-NEEDED BASIS, BASED ON CONTRACT REVIEWS AND EMPLOYEE INFORMATION. FORM 990, PART VI, LINES 15A AND 15B THE EXECUTIVE COMPENSATION AND GOVERNANCE COMMITTEE OF THE MEMBER SHALL BE THE EXECUTIVE COMPENSATION COMMITTEE OF TGEN. NOTWITHSTANDING THE FOREGOING, TGEN'S EXECUTIVE COMPENSATION AND GOVERNANCE COMMITTEE WILL ACT IN AN "ADVISE AND CONSENT" CAPACITY REVIEWING THE RECOMMENDATIONS OF THE PRESIDENT AND SCIENTIFIC DIRECTOR REGARDING THE COMPENSATION OF DISQUALIFIED PERSONS CONSISTENT WITH THE MEMBER'S COMPENSATION PHILOSOPHY AND WITHIN THE COMPENSATION RANGES APPROVED AT LEAST ANNUALLY BY THE MEMBER, AND FORWARDING FINAL RECOMMENDATIONS TO THE FULL TGEN BOARD FOR APPROVAL. DISQUALIFIED PERSONS (EXCEPT FOR THE PRESIDENT AND SCIENTIFIC DIRECTOR) WILL NOT BE PRESENT FOR, OR PARTICIPATE IN, COMMITTEE DELIBERATIONS CONCERNING THEIR COMPENSATION (OTHER THAN TO ANSWER QUESTIONS). THE PRESIDENT AND SCIENTIFIC DIRECTOR WILL PARTICIPATE IN THE DELIBERATIONS CONCERNING THE COMPENSATION OF DIRECT REPORTS. DURING THE DECISION MAKING PROCESS, THE COMMITTEE WILL ADHERE TO THE EXECUTIVE COMPENSATION PHILOSOPHY OF THE MEMBER. THE COMMITTEE IS AUTHORIZED (AND PROVIDED WITH SUFFICIENT FUNDING) TO ANNUALLY ENGAGE OUTSIDE INDEPENDENT COMPENSATION AND LEGAL ADVISORS, WHEN DEEMED NECESSARY AND ADVISABLE. THE COMMITTEE WILL COMPLY WITH THE "REBUTTABLE PRESUMPTION OF REASONABLENESS" UNDER SECTION 4958 OF THE INTERNAL REVENUE CODE WHENEVER POSSIBLE. THE COMMITTEE WILL REVIEW AND UNDERSTAND THE INTERNAL REVENUE CODE PROVISIONS DEALING WITH "EXCESS BENEFIT TRANSACTIONS CONCERNING DISQUALIFIED PERSONS' COMPENSATION." WHEN DEVELOPING A COMPENSATION PHILOSOPHY, TGEN KEPT IN MIND THE FOLLOWING FACTORS: - THE TGEN MISSION AND STRATEGY - THE TGEN CULTURE - TRENDS IN COMPENSATION IN THE EXTERNAL ENVIRONMENT - TRENDS IN RECRUITMENT OF NEW EMPLOYEES - TRENDS IN ORGANIZATIONAL EMPLOYEE TURNOVER - TGEN'S LIFE CYCLE STAGE THE COMPENSATION REVIEW PROCESS WAS LAST COMPLETED IN 2020. FORM 990, PART VI, LINE 19 TGEN'S ARTICLES OF INCORPORATION ARE AVAILABLE TO THE PUBLIC THROUGH THE ARIZONA CORPORATION COMMISSION. TGEN'S AUDITED FINANCIAL STATEMENTS AND ITS CONFLICT OF INTEREST POLICIES ARE AVAILABLE BY WRITTEN REQUEST MADE TO THE CFO AND CONFLICT OF INTEREST MANAGER, RESPECTIVELY. TGEN'S BYLAWS ARE NOT MADE AVAILABLE TO THE PUBLIC. FORM 990 PART IX LINE 11G DESCRIPTION:CONSORTIUM/CONTRACTUAL TOTAL FEES:3760493 FORM 990 PART IX LINE 11G DESCRIPTION:OUTSIDE RESEARCH SERVICES TOTAL FEES:3026368 FORM 990 PART IX LINE 11G DESCRIPTION:CONSULTING TOTAL FEES:2402766 FORM 990 PART IX LINE 11G DESCRIPTION:TEMPORARY SERVICES TOTAL FEES:200495 THE CENTER FOR TRANS DRUG DEVELOPMENT 445 N 5TH STREET SUITE 600 PHOENIX AZ 85004 432047329 DRUG DEVEL AZ 0 0 TGAM LLC TGEN ACCELERATORS LLC 445 N 5TH STREET SUITE 600 PHOENIX AZ 85004 753065445 GENOMICS AZ 0 0 TGEN TRANSLATIONAL SYSTEMS LLC 445 N 5TH STREET SUITE 600 PHOENIX AZ 85004 461309498 ADV RESEARCH AZ 0 0 TGEN VIDIUM LLC 445 N 5TH STREET SUITE 600 PHOENIX AZ 85004 753065445 ANIMAL DIAG AZ 18160 1174018 TGEN TGEN HEALTH VENTURES LLC 445 N 5TH STREET SUITE 600 PHOENIX AZ 85004 464520712 HEALTHCARE AZ 0 0 TGEN DROPWISE LLC 445 N 5TH STREET SUITE 600 PHOENIX AZ 85004 811959403 RESEARCH AZ 0 7740 TGAM LLC ID ORIGINS LLC 445 N 5TH STREET SUITE 600 PHOENIX AZ 85004 753065445 TECH TRANSFER AZ 0 0 TGAM LLC PROFERO LLC 445 N 5TH STREET SUITE 600 PHOENIX AZ 85004 753065445 LICENSING DE 0 0 TGEN METRICBIO LLC 445 N 5TH STREET SUITE 600 PHOENIX AZ 85004 814455083 RESEARCH DE 9100 10233 TGEN TGEN CLINICAL LAB LLC 445 N 5TH STREET SUITE 600 PHOENIX AZ 85004 383922888 HEALTHCARE AZ 0 0 TGEN HV LLC ASHION ANALYTICS LLC 445 N 5TH STREET SUITE 600 PHOENIX AZ 85004 454587602 HEALTHCARE AZ 24403041 10797988 ASHION PMED PRECISION MEDICINE FACILITIES LLC 445 N 5TH STREET SUITE 600 PHOENIX AZ 85004 822560090 REAL ESTATE AZ 7169077 48311512 TGEN TGEN RESEARCH INSTITUTE FOUNDATION 445 N 5TH STREET SUITE 120 PHOENIX AZ 85004 331092191 FUNDRAISING AZ 501(c)(3) 7 TGEN true CITY OF HOPE 1500 EAST DUARTE ROAD DUARTE CA 91010 953435919 FUNDRAISING CA 501(c)(3) 7 NA false CITY OF HOPE NATIONAL MEDICAL CENTER 1500 EAST DUARTE ROAD DUARTE CA 91010 951683875 HOSPITAL CA 501(c)(3) 3 CITY OF HOPE true BECKMAN RESEARCH INSTITUTE 1450 EAST DUARTE ROAD DUARTE CA 91010 953432210 RESEARCH CA 501(c)(3) 4 CITY OF HOPE true CITY OF HOPE MEDICAL FOUNDATION 1500 EAST DUARTE ROAD DUARTE CA 91010 272803222 HEALTHCARE CA 501(c)(3) 3 CITY OF HOPE true SOUTHERN CA RADIATION ONCOLOGY PO BOX 19067 DALLAS TX 75381 MGMT SERVICES CA NA N/A false false true false true false false false false false false true false true true false true false false TGEN RESEARCH INSTITUTE FOUNDATION c 10593325 ACTUAL COST TGEN RESEARCH INSTITUTE FOUNDATION q 1840783 ACTUAL COST CITY OF HOPE NATIONAL MEDICAL CENTER o 1271237 ACTUAL COST